drug posit growth
updat forecast estim may
conduct analyst
govern code ethics/cod conduct
polici secur trade polici
equival invest research
interest visit
primari analyst cover compani
stock
research may
estim may
price data may
rate updat may
currenc amount express
busi strategi outlook
methodolog valu compani
busi strategi outlook
johnson johnson stand alon leader across major
base develop research pipelin except cash flow
gener togeth creat wide econom moat
 hold leadership role divers healthcar segment
includ medic devic over-the-count product sever
pharmaceut market contribut close total
revenu pharmaceut divis boast sever industry-lead
drug includ immunolog drug remicad psoriasi drug
stelara medic devic group bring almost one third
sale compani hold control posit mani
area includ orthoped ethicon endo-surgeri surgic
devic consum divis larg round remain
busi line despit manufactur issu past
sever year group still hold mani brand strong price
research develop effort result next-gener
product pharmaceut group recent launch sever
new blockbust howev rel compani size
need increas number meaning drug late-stag
develop support long-term growth compani also
minim invas surgic tool
expenditur sale strong cash gener
enabl firm increas dividend past half
centuri expect continu also allow take
advantag acquisit opportun augment growth
divers oper segment coupl expect new product
insul compani patent loss rel
pharma firm contrast peer face
major near-term patent loss hard-to-mak
complex drug like slow gener competit
valuat summari forecast
financi summari forecast
historical/forecast data sourc morningstar estim may reflect adjust
johnson johnson world largest divers healthcar
compani three divis make firm pharmaceut medic devic
diagnost consum drug devic group repres close
sale drive major cash flow firm drug
divis focus follow therapeut area immunolog oncolog
neurolog pulmonari cardiolog metabol diseas devic
segment focus orthoped surgeri tool vision care
smaller area last segment consum focus babi care beauti
oral care over-the-count drug women health geograph
close half total revenu gener unit state
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
 provid solid updat pharmaceut busi
may johnson johnson host pharmaceut
updat invest commun highlight key
drug pipelin led us increas fair valu
estim stock continu trade
close fair valu suggest growth prospect
incorpor current stock price increas
visibl compani pipelin also strengthen
convict compani wide moat rest larg
firm abil develop innov new drug
 highlight key late-stag drug reach
market within next five year heavi focu
oncolog key late-stag drug bode well
compani price power scientif advanc
quicker develop time typic cancer
drug within cancer drug view egfr drug
multipl myeloma drug
well posit growth
drug compet drug
strong efficaci early-stag data look compel
drug gene therapi retin
drug depress drug vaccin
rsv notabl multipl sclerosi drug ponesimod
remain develop highlight drug
key drug potenti billion annual sale
outsid new drug launch pipelin also includ
develop new indic exist drug six-
month dose version invega schizophrenia new
indic tremfya psoriat arthriti crohn diseas
ulcer coliti expand cancer label darzalex
imbruvica erleada balversa drive futur growth
import drug drug face
increas competit expand label help
complet review pipelin pleas see annual
drug pipelin report moat remain secur innov
counter price gener headwind
increas fair valu estim
per share base increas project recent
drug hold strong price power typic reach
market shorter develop time overal within
core driver cash flow new immunolog oncolog
drug drive growth includ actelion acquisit
expect annual earn per share growth averag
next five year strong growth new
pipelin drug off-set patent loss
margin
next sever year wane
cost-remedi effort consum group
increas cost-contain effort throughout firm
help off-set margin pressur due loss patent
protect sever high-margin drug
immunolog drug remicad also follow
expect reduc depend asset sale
firm use occasion boost overal earn
larg basi low volatil cash flow
divers inelast product portfolio rate johnson
 johnson uncertainti low scenario analysi
assum base-cas fair valu estim bull
case probabl bear case
probabl project fair valu estim rel
base case scenario analysi show minor varianc
henc low fair valu uncertainti rate key factor
affect scenario analysi includ degre
success drug pipelin along magnitud
market pressur current market drug
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
group consum product repres
total sale respect addit within
segment one product domin sale lipitor
despit carri lower-margin divis
maintain strong price power post gross
margin past five year valid
strong competit posit
johnson johnson effort support robust revenu
base pharmaceut compani recent launch
sever new blockbust allow johnson
johnson escap larg unscath upcom patent
expir effort medic devic includ
minim invas surgic tool help maintain
leadership sever medic devic area well
remain high sever devic product
exampl physician switch vendor hip knee
devic could take week month learn new
product keep physician tie compani
consum side new product
advanc combin solid brand power
reinforc market campaign sustain solid
compani face manag patent loss next
year price power core franchis
rel stabl turn macro environ
compani face sever headwind make solid
strateg move address challeng neg
side risk-sensit food drug administr
gener approv safe drug drug
high-ne area cancer also managed-car
pharmaci benefit manag consolid past
decad use grow size demand
lower drug price reduc coverag less innov
drug forc drug firm push true innov
importantli potenti pressur remicad
biosimilar unknown regulatori impact on-going
litig surround devic talc powder also weigh
certainti
believ johnson johnson carri one widest
moat healthcar sector support intellectu
properti drug group switch cost devic
segment strong brand power consum group
compani divers revenu base strong pipelin
robust cash flow gener creat wide econom
candid smaller biotechnolog compani look
partner new drug strengthen johnson
johnson abil bring new product market
johnson johnson divers oper major pillar
support wide moat compani hold leadership
role number segment includ medic devic
over-the-counter medicin sever drug market
compani overli depend one particular oper
segment pharmaceut busi medic devic
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
reduc power compani distribut network
 govern evalu compar
effect program aggress price
negoti rais bar futur innov
johnson johnson face sever headwind pipelin
focus innov treatment area unmet
medic area oncolog immunolog
payer coverag price power remain strong outsid
pipelin strong entrench medic devic
consum good give firm relief
pressur pharmaceut group
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
oth major near-term patent loss
product hard manufactur
ojnj late-stag drug pipelin rel weak
size compani could creat long-term
hurdl growth
odivers healthcar segment help insul
downturn economi offer defens
growth opportun steadi like grow
osever johnson johnson key drug
pipelin drug specialti drug tend carri
strong price power well lower regulatori
hurdl approv
oleg action regard product recal hip knee
replac along sever consum product
could damag compani brand power cost
billion dollar creat distract
osever johnson johnson import drug
face increas competit could slow
growth rate drug group
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
equival begin period
total avail debt servic
oblig commit
total oblig commit
adjust free
gener
gener revolv adjust
commit
johnson johnson hold one strongest financi
posit healthcar sector project
debt/ebitda recent acquisit
actelion put dent compani cash balanc
annual free cash flow close billion
compani sound financi shape even expect
bolt-on acquisit share repurchas
compani remain solid financi foot
oper standpoint patent loss mitig sever
divers oper line medic devic consum
product cash flow remain rel stabl
addit expect share repurchas next
sever year draw share count
johnson johnson need overcom sever roadblock
product metal-on-met hip knee implant
sever product recal could damag sterl
reput longer term compani face typic
healthcar risk reduc price power
govern pharmaci benefit manag regulatori
delay nonapprov well increasingli aggress
gener competit small-molecul drug
biolog particular biosimilar risk remicad
increas sever biosimilar work gain
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
ceo/chairman board/
repres date owner name posit common share held report holder issuer
share
fund
share
fund
overal view stewardship johnson johnson
rel standard firm good record
make sound capit deploy decis
consist gener return invest capit
cost capit major recal recent potenti
overpay actelion poor turnaround time
address manufactur problem certain key divis
lead us balanc view compani
weldon step top posit
lead johnson johnson sinc given
weldon age rigor process find successor
see chang leadership red flag gorski
bring strong record industri experi date back
began industri pharmaceut
johnson johnson
subsequ advanc mani manag
posit drug devic divis johnson
johnson along manageri post novarti give
broad experi need run massiv health
conglomer first major test gorski leadership
billion acquisit orthoped devic firm
synth larg driven gorski head
johnson johnson devic unit believ
acquisit ad import exposur emerg market
trauma devic appear small
impact valuat price paid synth larg
account
increment benefit gain
acquisit second major test gorski recent
complet actelion deal skeptic
abl creat much valu sharehold due high
acquisit price rel fair valu
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
 provid solid updat pharmaceut busi
may johnson johnson host pharmaceut
updat invest commun highlight key
drug pipelin led us increas fair valu
estim stock continu trade
close fair valu suggest growth prospect
incorpor current stock price increas
visibl compani pipelin also strengthen
convict compani wide moat rest larg
firm abil develop innov new drug
 highlight key late-stag drug reach
market within next five year heavi focu
oncolog key late-stag drug bode well
compani price power scientif advanc
quicker develop time typic cancer
drug within cancer drug view egfr drug
multipl myeloma drug
well posit growth
drug compet drug
strong efficaci early-stag data look compel
drug gene therapi retin
drug depress drug vaccin
rsv notabl multipl sclerosi drug ponesimod
remain develop highlight drug
key drug potenti billion annual sale
outsid new drug launch pipelin also includ
develop new indic exist drug six-
month dose version invega schizophrenia new
indic tremfya psoriat arthriti crohn diseas
ulcer coliti expand cancer label darzalex
imbruvica erleada balversa drive futur growth
import drug drug face
increas competit expand label help
complet review pipelin pleas see annual
drug pipelin report moat remain secur innov
counter price gener headwind
 post solid increas gener competit
weigh full-year outlook apr
buoy strong drug sale solid expens
result slightli ahead consensu expect
expect major chang fair valu
estim base minor out-performance recent drug
launch oncolog immunolog support total
oper drug sale growth year year
outpac devic consum sale
strong drug sale reinforc intang asset moat
sourc back wide moat rate
biosimilar remicad
first-quart drug sale solid expect
divis growth slow later year due increas
competit cancer drug zytiga velcad along
immunolog weigh total drug sale believ
factor play part manag decis sell
advanc steril product record gain
adjust earn maintain overal earn growth
year follow expect gener pressur
eas recent launch drug return drug group
steadi growth
medic devic segment continu acceler
growth offset weak consum group strong
growth devic intervent solut includ
electrophysiolog atrial fibril help off-set
rel flat oper growth orthoped
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
consum slow overal industri growth weigh sale
also believ strong brand power hold
well increasingli import on-line sale
 hold expens check slightli better
expect one-tim legal charg million
concern probabl relat talcum litig
continu expect minor impact fair valu
estim base litig model close
billion relat charg
look deeper pipelin continu advanc
drug portfolio recent approv spravato
treatment-resist depress balversa bladder
cancer help posit compani long-term growth
complet review pipelin pleas see annual
drug pipelin report moat remain secur innov
counter price gener headwind
 post steadi led drug increas
gener pressur weigh outlook jan
johnson johnson report fourth-quart result
larg line expect
consensu expect major chang
fair valu estim base result
guidanc larg line expect
littl weak expect sale growth off-set
higher expect incom overal expect js
wide moat remain intact support divers group
patent-protect drug strong brand consum
product innov medic devic
quarter drug sale growth oper
help buoy total sale growth expect gener
competit acceler weigh total
growth close flat year ahead strong oncolog
immunolog pulmonari sale drove growth late
gener competit cancer drug zytiga velcad
along continu biosimilar pressur immunolog
drug remicad like slow total drug sale
offset slow expect drug sale anticip
higher incom slightli stronger consum
medic devic sale lead earn growth
oper use incom
drive earn concern strategi divest
product lack sustain believ
capac use one-tim divestitur off-set
increas pressur like gener exposur expect
limit basi like firm manag
heavi competit pressur hepat drug
turn talcum powder front compani reiter
high convict safeti product firm
also took gener litig expens billion
quarter may affect talc powder
litig continu expect major impact
 fair valu base litig model
close billion charg relat issu
pipelin side continu make stride
improv portfolio cancer drug erdafitinib
depress drug esketamin review
approv hold modest expect drug
base drug target smaller patient size
efficaci concern esketamin complet review
 pipelin pleas see annual pipelin report titl
annual drug pipelin report moat remain secur
innov counter price gener headwind
legal concern weigh johnson johnson media
media report highlight legal concern johnson
johnson talc powder weigh stock price
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
expect major chang fair valu estim
base report johnson johnson face
case relat use talc powder caus person
injuri cancer mani case legal issu
front compani mani year expect
case litig sever year case
alreadi decid shown mix outcom close
half verdict go compani
half support compani expect case
appeal litig compani alreadi
establish legal defens accrual help litig
case overal expect legal case
disrupt wide moat firm sourc moat
innov brand power howev brand power
consum relat product may feel
increas pressur case continu
media report sever relationship johnson
 johnson talc powder asbesto cite could
lead health problem believ rigor
test year provid legal protect
major case uncertainti remain
around credibl legal claim made
believ major case motiv
tri link unrel diseas talc powder use
effort gain settlement litig
case one one expect wear
plaintiff group end settlement caus
major impact compani stock price remind
 face litig concern surround
metal-on-met hip compani success navig
payment billion dollar without caus major
impact valuat
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
financi summari forecast
fiscal year end decemb
earn interest tax
return asset
return equiti
valuat summari forecast
equiti
pre-tax debt
weight averag capit
addit estim scenario avail download http //select morningstar com
equival
data tabl repres base-cas forecast compani report
currenc begin current year fair valu estim may differ
equiti valu per share shown due time valu money adjust case
probability-weight scenario analysi perform
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
fiscal year end decemb
good sold
depreci amort report separ
impair charg report separ
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
